An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Running, not enrolling · Phase 2

Conditions studied: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer

In brief

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.

Key facts

Study ID

NCT02955940

Run by

Incyte Corporation

People needed

10

Starts

2016-11-30

Expected to finish

2027-09-30

Last updated by the study team

2025-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
• Currently tolerating treatment in the parent protocol.
• Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
• Have at least stable disease, as determined by the investigator.
• Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.

You may not qualify if…

• Has been permanently discontinued from study treatment in the parent study for any reason.
• Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.

Where it is running

• UCLA Healthcare Hematology-Oncology — Santa Monica, California, United States
• University of Louisville — Louisville, Kentucky, United States
• New York Oncology Hematology Pc. — Clifton Park, New York, United States
• Tennessee Oncology — Nashville, Tennessee, United States
• University of Texas M. D. Anderson Cancer Center — Houston, Texas, United States
• Renovatio Clinical Consultants Llc — The Woodlands, Texas, United States
• Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii — Krakow, Poland
• Samodzielny Publiczny Szpital Kliniczny — Lublin, Poland
• Instytut Hematologii I Transfuzjologii — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.